RECURRENT ENDOMETRIAL CANCER
Clinical trials for RECURRENT ENDOMETRIAL CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ENDOMETRIAL CANCER trials appear
Sign up with your email to follow new studies for RECURRENT ENDOMETRIAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for Tough-to-Treat uterine cancer
Disease control OngoingThis phase 2 trial tests two drugs—niraparib and TSR-042 (dostarlimab)—in 51 women with recurrent endometrial cancer that has progressed after platinum chemotherapy. The goal is to see if these drugs can shrink or stabilize tumors. Niraparib blocks a protein that helps cancer cel…
Matched conditions: RECURRENT ENDOMETRIAL CANCER
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New Antibody-Drug conjugate takes aim at Hard-to-Treat gynaecological cancers
Disease control OngoingThis early-stage trial is testing a new drug called IMGN151 in 256 adults with recurrent gynaecological cancers, including ovarian, endometrial, and cervical cancers. The drug is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to cells that have a s…
Matched conditions: RECURRENT ENDOMETRIAL CANCER
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC